000			01337cas a2200337 a 4500
005			20250918011702.0
008			090630c20069999enk x b 0 0eng c
020			_a9780521862554 _cRM664.20
039		9	_a200911051535 _bazhari _c200911051340 _dmustaffa _c200911051336 _dmustaffa _c200910261500 _dmustaffa _y06-30-2009 _zrazalis
040			_aUKM
060			_aWL300 _b.P964 2008 9
090			_aWL300.P964 2008 9
222	0	0	_aProgress in neurotherapeutics and neuropsychopharmacology 2008 / _ceditor-in-chief, Jeffrey L. Cummings
245	0	0	_aProgress in neurotherapeutics and neuropsychopharmacology 2008 / _ceditor-in-chief, Jeffrey L. Cummings
246	3	0	_aNeurotherapeutics and neuropsychopharmacology
260			_aCambridge [England] ; _aNew York : _bCambridge University Press, _c2008
300			_axii, 299 p. : _bill. ; _c25 cm.
650		2	_aBrain Diseases _xdrug therapy
650		2	_aNeuropharmacology
650		2	_aCentral Nervous System _xdrug effects
650		2	_aMental Disorders _xdrug therapy
650		2	_aClinical trials
700	1		_aCummings, Jeffrey L.
907			_a.b14527881 _b2021-02-22 _c2019-11-12
942			_c01 _n0 _kWL300.P964 2008 9
914			_avtls003412564
990			_amk
991			_aProgram Psikologi
998			_ad _b2009-04-06 _cs _dpj _feng _genk _y0 _z.b14527881
999			_c445019 _d445019